T1	tradename 0 8	ABRAXANE
T3	activeingredient 37 47	paclitaxel
T5	tradename 170 178	ABRAXANE
T7	tradename 242 262	ABRAXANE.  ABRAXANE
T9	nanoparticle 291 315	paclitaxel protein-bound
T11	tradename 317 317	
T13	nanoparticle 317 326	particles
T15	corecomposition 355 368	albumin-bound
T17	fdaapprovaldate 394 398	2005
T19	tradename 502 510	ABRAXANE
T21	activeingredient 787 797	PACLITAXEL
T23	tradename 1085 1093	ABRAXANE
T25	chemoclass 1099 1120	microtubule inhibitor
T27	tradename 1154 1154	
T29	indication 1154 1178	Metastatic breast cancer
T31	indication 1414 1459	metastatic non-small cell lung cancer (NSCLC)
T33	tradename 1603 1603	
T35	indication 1603 1644	Metastatic adenocarcinoma of the pancreas
T37	tradename 1785 1785	
T39	indication 1785 1810	Metastatic Breast Cancer:
T41	tradename 1833 1841	ABRAXANE
T43	dose 1845 1854	260 mg/m2
T45	routeofadministration 1855 1868	intravenously
T47	tradename 1907 1907	
T49	indication 1907 1934	Non-Small Cell Lung Cancer:
T51	tradename 1957 1965	ABRAXANE
T53	dose 1969 1978	100 mg/m2
T55	routeofadministration 1979 1992	intravenously
T57	tradename 2123 2132	ABRAXANE.
T59	tradename 2140 2140	
T61	indication 2140 2171	Adenocarcinoma of the Pancreas:
T63	tradename 2194 2202	ABRAXANE
T65	dose 2206 2215	125 mg/m2
T67	routeofadministration 2216 2229	intravenously
T69	tradename 2373 2382	ABRAXANE.
T71	tradename 2408 2416	ABRAXANE
T73	tradename 2500 2508	ABRAXANE
T75	indication 2526 2567	metastatic adenocarcinoma of the pancreas
T77	indication 2640 2681	metastatic adenocarcinoma of the pancreas
T79	activeingredient 3240 3250	paclitaxel
T81	corecomposition 3265 3278	albumin-bound
T83	tradename 3508 3517	ABRAXANE.
T85	tradename 3599 3607	ABRAXANE
T87	tradename 3874 3882	ABRAXANE
T89	tradename 3926 3934	ABRAXANE
T91	tradename 4131 4139	ABRAXANE
T93	tradename 4212 4220	ABRAXANE
T95	activeingredient 4387 4397	paclitaxel
T97	tradename 4494 4502	ABRAXANE
T99	tradename 4747 4756	ABRAXANE.
T101	tradename 4806 4815	ABRAXANE.
T103	indication 4954 4978	metastatic breast cancer
T105	adversereaction 4983 4991	alopecia
T107	adversereaction 4993 5004	neutropenia
T109	adversereaction 5006 5024	sensory neuropathy
T111	adversereaction 5026 5038	abnormal ECG
T113	adversereaction 5040 5056	fatigue/asthenia
T115	adversereaction 5058 5076	myalgia/arthralgia
T117	adversereaction 5078 5091	AST elevation
T119	adversereaction 5093 5123	alkaline phosphatase elevation
T121	adversereaction 5125 5131	anemia
T123	adversereaction 5133 5139	nausea
T125	adversereaction 5141 5151	infections
T127	adversereaction 5157 5166	diarrhea.
T129	indication 5226 5231	NSCLC
T131	adversereaction 5236 5242	anemia
T133	adversereaction 5244 5255	neutropenia
T135	adversereaction 5257 5273	thrombocytopenia
T137	adversereaction 5275 5283	alopecia
T139	adversereaction 5285 5306	peripheral neuropathy
T141	adversereaction 5308 5314	nausea
T143	adversereaction 5320 5328	fatigue.
T145	tradename 5388 5396	ABRAXANE
T147	indication 5400 5430	adenocarcinoma of the pancreas
T149	adversereaction 5435 5446	neutropenia
T151	adversereaction 5448 5455	fatigue
T153	adversereaction 5457 5478	peripheral neuropathy
T155	adversereaction 5480 5486	nausea
T157	adversereaction 5488 5496	alopecia
T159	adversereaction 5498 5514	peripheral edema
T161	adversereaction 5516 5524	diarrhea
T163	adversereaction 5526 5533	pyrexia
T165	adversereaction 5535 5543	vomiting
T167	adversereaction 5545 5563	decreased appetite
T169	adversereaction 5565 5569	rash
T171	adversereaction 5575 5587	dehydration.
T173	company 5642 5661	Celgene Corporation
T175	tradename 5861 5869	ABRAXANE
T177	indication 6124 6148	Metastatic Breast Cancer
T179	indication 6155 6181	Non-Small Cell Lung Cancer
T181	indication 6188 6218	Adenocarcinoma of the Pancreas
T183	indication 6255 6279	Metastatic Breast Cancer
T185	indication 6287 6313	Non-Small Cell Lung Cancer
T187	indication 6320 6350	Adenocarcinoma of the Pancreas
T189	routeofadministration 6526 6537	Intravenous
T191	corecomposition 6782 6789	Albumin
T193	indication 6899 6923	Metastatic Breast Cancer
T195	indication 6961 6987	Non-Small Cell Lung Cancer
T197	indication 7024 7054	Adenocarcinoma of the Pancreas
T199	tradename 7093 7101	ABRAXANE
T201	activeingredient 7112 7122	Paclitaxel
T203	indication 7596 7620	Metastatic Breast Cancer
T205	indication 7629 7655	Non-Small Cell Lung Cancer
T207	indication 7664 7694	Adenocarcinoma of the Pancreas
T209	tradename 7969 7977	ABRAXANE
T211	nanoparticle 8006 8040	paclitaxel protein-bound particles
T213	corecomposition 8069 8082	albumin-bound
T215	tradename 8126 8134	ABRAXANE
T217	tradename 8454 8462	ABRAXANE
T219	corecomposition 8572 8579	albumin
T221	activeingredient 8588 8598	paclitaxel
T223	activeingredient 8730 8740	PACLITAXEL
T225	indication 8787 8811	Metastatic Breast Cancer
T227	tradename 8813 8821	ABRAXANE
T229	indication 9081 9107	Non-Small Cell Lung Cancer
T231	tradename 9109 9117	ABRAXANE
T233	indication 9183 9220	metastatic non-small cell lung cancer
T235	indication 9338 9368	Adenocarcinoma of the Pancreas
T237	tradename 9370 9378	ABRAXANE
T239	indication 9438 9479	metastatic adenocarcinoma of the pancreas
T241	indication 9550 9574	Metastatic Breast Cancer
T243	indication 9622 9646	metastatic breast cancer
T245	tradename 9728 9736	ABRAXANE
T247	dose 9740 9749	260 mg/m2
T249	routeofadministration 9763 9776	intravenously
T251	frequency 9793 9807	every 3 weeks.
T253	indication 9814 9840	Non-Small Cell Lung Cancer
T255	tradename 9866 9874	ABRAXANE
T257	dose 9878 9887	100 mg/m2
T259	routeofadministration 9907 9918	intravenous
T261	tradename 10060 10068	ABRAXANE
T263	indication 10106 10136	Adenocarcinoma of the Pancreas
T265	tradename 10162 10170	ABRAXANE
T267	dose 10174 10183	125 mg/m2
T269	routeofadministration 10203 10214	intravenous
T271	tradename 10328 10336	ABRAXANE
T273	tradename 10719 10727	ABRAXANE
T275	indication 10745 10786	metastatic adenocarcinoma of the pancreas
T277	tradename 10854 10862	ABRAXANE
T279	tradename 11225 11233	ABRAXANE
T281	indication 11241 11250	MBC NSCLC
T283	indication 11626 11629	MBC
T285	indication 11632 11656	Metastatic Breast Cancer
T287	indication 11658 11663	NSCLC
T289	indication 11666 11693	Non-Small Cell Lung Cancer.
T291	dose 11886 11895	260 mg/m2
T293	indication 11914 11938	metastatic breast cancer
T295	dose 11942 11951	100 mg/m2
T297	indication 11970 11996	non-small cell lung cancer
T299	tradename 12287 12287	
T301	indication 12287 12311	Metastatic Breast Cancer
T303	adversereaction 12337 12355	severe neutropenia
T305	tradename 12451 12459	ABRAXANE
T307	dose 12498 12507	220 mg/m2
T309	tradename 12534 12546	ABRAXANE. 
T311	adversereaction 12564 12582	severe neutropenia
T313	adversereaction 12586 12611	severe sensory neuropathy
T315	dose 12657 12666	180 mg/m2
T317	adversereaction 12674 12700	Grade 3 sensory neuropathy
T319	tradename 12809 12817	ABRAXANE
T321	tradename 12913 12914	 
T323	indication 12914 12940	Non-Small Cell Lung Cancer
T325	tradename 12960 12968	ABRAXANE
T327	tradename 13599 13607	ABRAXANE
T329	tradename 13664 13672	ABRAXANE
T331	adversereaction 13677 13709	Grade 3-4 peripheral neuropathy.
T333	tradename 13718 13726	ABRAXANE
T335	adversereaction 13779 13800	peripheral neuropathy
T337	indication 14003 14008	NSCLC
T339	tradename 14051 14059	ABRAXANE
T341	tradename 14558 14561	 
T343	indication 14561 14591	Adenocarcinoma of the Pancreas
T345	indication 14632 14662	adenocarcinoma of the pancreas
T347	indication 14773 14803	Adenocarcinoma of the Pancreas
T349	tradename 14817 14825	ABRAXANE
T351	indication 15079 15109	adenocarcinoma of the pancreas
T353	indication 15284 15314	Adenocarcinoma of the Pancreas
T355	tradename 15370 15378	ABRAXANE
T357	indication 16078 16108	adenocarcinoma of the pancreas
T359	indication 16214 16244	Adenocarcinoma of the Pancreas
T361	tradename 16268 16276	ABRAXANE
T363	tradename 16844 16852	ABRAXANE
T365	activeingredient 16910 16920	paclitaxel
T367	tradename 16972 16983	ABRAXANE. 
T369	tradename 17020 17028	ABRAXANE
T371	activeingredient 17189 17199	paclitaxel
T373	tradename 17254 17262	ABRAXANE
T375	adversereaction 17372 17385	extravasation
T377	tradename 17519 17527	ABRAXANE
T379	adversereaction 17582 17608	infusion-related reactions
T381	adversereaction 17666 17692	hypersensitivity reactions
T383	tradename 17748 17757	ABRAXANE.
T385	tradename 17848 17860	ABRAXANE. 
T387	tradename 17922 17930	ABRAXANE
T389	routeofadministration 18034 18045	Intravenous
T391	tradename 18063 18071	ABRAXANE
T393	activeingredient 19096 19107	paclitaxel.
T395	tradename 19611 19619	ABRAXANE
T397	tradename 19867 19875	ABRAXANE
T399	tradename 20132 20140	ABRAXANE
T401	tradename 20416 20424	ABRAXANE
T403	tradename 21066 21074	ABRAXANE
T405	activeingredient 21401 21411	paclitaxel
T407	corecomposition 21426 21439	albumin-bound
T409	tradename 21512 21521	 ABRAXANE
T411	tradename 21678 21686	ABRAXANE
T413	tradename 21785 21785	
T415	adversereaction 21785 21808	Bone marrow suppression
T417	adversereaction 21820 21832	neutropenia)
T419	tradename 21883 21895	ABRAXANE. 
T421	adversereaction 21916 21937	Grade 3-4 neutropenia
T423	indication 21971 22001	metastatic breast cancer (MBC)
T425	indication 22024 22058	non-small cell lung cancer (NSCLC)
T427	adversereaction 22117 22130	myelotoxicity
T429	indication 22224 22228	MBC)
T431	indication 22256 22261	NSCLC
T433	indication 22270 22288	pancreatic cancer)
T435	tradename 22310 22318	ABRAXANE
T437	tradename 22505 22513	ABRAXANE
T439	tradename 22542 22550	ABRAXANE
T441	indication 22597 22600	MBC
T443	indication 22604 22610	NSCLC.
T445	indication 22629 22632	MBC
T447	tradename 22679 22687	ABRAXANE
T449	indication 22813 22818	NSCLC
T451	tradename 22938 22946	ABRAXANE
T453	indication 23253 23283	adenocarcinoma of the pancreas
T455	tradename 23294 23302	ABRAXANE
T457	tradename 23677 23677	
T459	adversereaction 23677 23695	Sensory neuropathy
T461	adversereaction 23788 23819	Grade 1 or 2 sensory neuropathy
T463	adversereaction 23879 23905	Grade 3 sensory neuropathy
T465	tradename 23925 23933	ABRAXANE
T467	indication 23981 24005	metastatic breast cancer
T469	indication 24050 24055	NSCLC
T471	tradename 24137 24145	ABRAXANE
T473	adversereaction 24191 24197	Sepsis
T475	tradename 24199 24199	
T477	adversereaction 24199 24205	Sepsis
T479	adversereaction 24249 24260	neutropenia
T481	tradename 24274 24282	ABRAXANE
T483	co-administereddrug 24303 24315	gemcitabine.
T485	adversereaction 24521 24540	febrile neutropenia
T487	tradename 24552 24560	ABRAXANE
T489	co-administereddrug 24565 24576	gemcitabine
T491	adversereaction 24710 24721	Pneumonitis
T493	tradename 24723 24723	
T495	adversereaction 24723 24734	Pneumonitis
T497	tradename 24811 24819	ABRAXANE
T499	co-administereddrug 24840 24852	gemcitabine.
T501	adversereaction 24896 24907	pneumonitis
T503	tradename 24922 24930	ABRAXANE
T505	co-administereddrug 24935 24946	gemcitabine
T507	adversereaction 24978 24990	pneumonitis.
T509	adversereaction 25061 25072	pneumonitis
T511	tradename 25113 25121	ABRAXANE
T513	co-administereddrug 25126 25138	gemcitabine.
T515	adversereaction 25145 25161	Hypersensitivity
T517	adversereaction 25190 25216	hypersensitivity reactions
T519	adversereaction 25228 25250	anaphylactic reactions
T521	adversereaction 25306 25331	hypersensitivity reaction
T523	tradename 25335 25343	ABRAXANE
T525	activeingredient 25451 25461	paclitaxel
T527	tradename 25522 25530	ABRAXANE
T529	tradename 25798 25806	ABRAXANE
T531	tradename 25910 25918	ABRAXANE
T533	indication 25955 25996	metastatic adenocarcinoma of the pancreas
T535	corecomposition 26307 26314	Albumin
T537	tradename 26324 26332	ABRAXANE
T539	corecomposition 26342 26349	albumin
T541	corecomposition 26712 26720	albumin.
T543	tradename 26745 26753	ABRAXANE
T545	activeingredient 26834 26844	paclitaxel
T547	corecomposition 26859 26872	albumin-bound
T549	tradename 27212 27221	ABRAXANE.
T551	tradename 27487 27495	ABRAXANE
T553	tradename 27615 27623	ABRAXANE
T555	tradename 28024 28032	ABRAXANE
T557	indication 28036 28060	metastatic breast cancer
T559	adversereaction 28065 28073	alopecia
T561	adversereaction 28075 28086	neutropenia
T563	adversereaction 28088 28106	sensory neuropathy
T565	adversereaction 28108 28120	abnormal ECG
T567	adversereaction 28122 28138	fatigue/asthenia
T569	adversereaction 28140 28158	myalgia/arthralgia
T571	adversereaction 28160 28173	AST elevation
T573	adversereaction 28175 28205	alkaline phosphatase elevation
T575	adversereaction 28207 28213	anemia
T577	adversereaction 28215 28221	nausea
T579	adversereaction 28223 28233	infections
T581	adversereaction 28239 28247	diarrhea
T583	tradename 28332 28340	ABRAXANE
T585	co-administereddrug 28361 28372	carboplatin
T587	indication 28377 28403	non-small cell lung cancer
T589	adversereaction 28408 28414	anemia
T591	adversereaction 28416 28427	neutropenia
T593	adversereaction 28429 28445	thrombocytopenia
T595	adversereaction 28447 28455	alopecia
T597	adversereaction 28457 28478	peripheral neuropathy
T599	adversereaction 28480 28486	nausea
T601	adversereaction 28492 28499	fatigue
T603	tradename 28576 28584	ABRAXANE
T605	co-administereddrug 28605 28616	carboplatin
T607	indication 28621 28647	non-small cell lung cancer
T609	adversereaction 28652 28658	anemia
T611	adversereaction 28668 28677	pneumonia
T613	tradename 28761 28769	ABRAXANE
T615	adversereaction 28774 28785	neutropenia
T617	adversereaction 28792 28808	thrombocytopenia
T619	adversereaction 28819 28840	peripheral neuropathy
T621	tradename 28913 28921	ABRAXANE
T623	adversereaction 28926 28937	neutropenia
T625	adversereaction 28945 28961	thrombocytopenia
T627	adversereaction 28973 28979	anemia
T629	tradename 29057 29065	ABRAXANE
T631	adversereaction 29077 29088	neutropenia
T633	adversereaction 29096 29112	thrombocytopenia
T635	adversereaction 29124 29130	anemia
T637	tradename 29176 29184	ABRAXANE
T639	co-administereddrug 29205 29216	gemcitabine
T641	indication 29221 29246	pancreatic adenocarcinoma
T643	tradename 29377 29385	ABRAXANE
T645	adversereaction 29390 29401	neutropenia
T647	adversereaction 29403 29410	fatigue
T649	adversereaction 29412 29433	peripheral neuropathy
T651	adversereaction 29435 29441	nausea
T653	adversereaction 29443 29451	alopecia
T655	adversereaction 29453 29469	peripheral edema
T657	adversereaction 29471 29479	diarrhea
T659	adversereaction 29481 29488	pyrexia
T661	adversereaction 29490 29498	vomiting
T663	adversereaction 29500 29518	decreased appetite
T665	adversereaction 29520 29524	rash
T667	adversereaction 29530 29542	dehydration.
T669	tradename 29589 29597	ABRAXANE
T671	adversereaction 29640 29647	pyrexia
T673	adversereaction 29654 29665	dehydration
T675	adversereaction 29672 29681	pneumonia
T677	adversereaction 29691 29699	vomiting
T679	tradename 29784 29792	ABRAXANE
T681	adversereaction 29797 29818	peripheral neuropathy
T683	adversereaction 29825 29832	fatigue
T685	adversereaction 29842 29858	thrombocytopenia
T687	tradename 29932 29940	ABRAXANE
T689	adversereaction 29945 29956	neutropenia
T691	adversereaction 29967 29988	peripheral neuropathy
T693	tradename 30065 30073	ABRAXANE
T695	adversereaction 30085 30096	neutropenia
T697	adversereaction 30104 30120	thrombocytopenia
T699	adversereaction 30128 30135	fatigue
T701	adversereaction 30142 30163	peripheral neuropathy
T703	adversereaction 30171 30177	anemia
T705	adversereaction 30187 30195	diarrhea
T707	indication 30238 30262	Metastatic Breast Cancer
T709	tradename 30407 30415	ABRAXANE
T711	activeingredient 30419 30429	paclitaxel
T713	indication 30461 30486	metastatic breast cancer.
T715	tradename 30656 30666	ABRAXANE 
T717	tradename 30697 30697	
T719	activeingredient 30697 30707	Paclitaxel
T721	adversereaction 30760 30771	Neutropenia
T723	tradename 30830 30830	
T725	adversereaction 30832 30848	Thrombocytopenia
T727	tradename 30907 30907	
T729	adversereaction 30907 30913	Anemia
T731	tradename 30956 30956	
T733	adversereaction 30956 30966	Infections
T735	adversereaction 30975 30994	Febrile Neutropenia
T737	adversereaction 31001 31019	Neutropenic Sepsis
T739	adversereaction 31032 31040	Bleeding
T741	indication 31134 31151	Metastatic Breast
T743	tradename 31153 31154	 
T745	indication 31154 31160	Cancer
T747	tradename 31228 31236	ABRAXANE
T749	dose 31237 31246	260 mg/m2
T751	tradename 31268 31268	
T753	activeingredient 31268 31278	Paclitaxel
T755	dose 31289 31298	175 mg/m2
T757	tradename 31318 31319	 
T759	adversereaction 31319 31335	Hypersensitivity
T761	tradename 31337 31337	
T763	adversereaction 31337 31346	Reactionc
T765	tradename 31435 31435	
T767	adversereaction 31435 31446	Bradycardia
T769	tradename 31464 31464	
T771	adversereaction 31464 31475	Hypotension
T773	tradename 31483 31483	
T775	adversereaction 31483 31512	Severe Cardiovascular Eventsd
T777	tradename 31518 31518	
T779	adversereaction 31518 31530	Abnormal ECG
T781	adversereaction 31602 31607	Cough
T783	tradename 31615 31615	
T785	adversereaction 31615 31622	Dyspnea
T787	tradename 31630 31630	
T789	adversereaction 31630 31648	Sensory Neuropathy
T791	tradename 31694 31694	
T793	adversereaction 31694 31701	Myalgia
T795	adversereaction 31704 31714	Arthralgia
T797	tradename 31759 31759	
T799	adversereaction 31759 31767	Asthenia
T801	tradename 31812 31812	
T803	adversereaction 31812 31833	Fluid Retention/Edema
T805	adversereaction 31898 31904	Nausea
T807	tradename 31966 31966	
T809	adversereaction 31966 31974	Vomiting
T811	tradename 32028 32028	
T813	adversereaction 32028 32036	Diarrhea
T815	tradename 32090 32090	
T817	adversereaction 32090 32099	Mucositis
T819	tradename 32152 32153	 
T821	adversereaction 32153 32161	Alopecia
T823	tradename 32211 32211	
T825	adversereaction 32211 32231	Bilirubin Elevations
T827	tradename 32240 32240	
T829	adversereaction 32240 32271	Alkaline Phosphatase Elevations
T831	tradename 32312 32312	
T833	adversereaction 32312 32335	Injection Site Reaction
T835	activeingredient 32445 32455	Paclitaxel
T837	adversereaction 32547 32563	hypersensitivity
T839	adversereaction 32571 32579	flushing
T841	adversereaction 32581 32588	dyspnea
T843	adversereaction 32590 32600	chest pain
T845	adversereaction 32602 32614	hypotension)
T847	adversereaction 32770 32781	Neutropenia
T849	indication 32839 32863	metastatic breast cancer
T851	dose 32991 33000	260 mg/m2
T853	activeingredient 33039 33049	paclitaxel
T855	dose 33073 33082	175 mg/m2
T857	adversereaction 33085 33097	Pancytopenia
T859	tradename 33219 33231	ABRAXANE. 
T861	tradename 33428 33436	ABRAXANE
T863	tradename 33563 33571	ABRAXANE
T865	activeingredient 33626 33636	paclitaxel
T867	corecomposition 33656 33663	albumin
T869	tradename 34038 34046	ABRAXANE
T871	tradename 34989 35000	ABRAXANE. 
T873	tradename 35130 35138	ABRAXANE
T875	tradename 35221 35229	ABRAXANE
T877	tradename 35398 35406	ABRAXANE
T879	tradename 35811 35819	ABRAXANE
T881	tradename 36124 36132	ABRAXANE
T883	tradename 36270 36278	ABRAXANE
T885	activeingredient 36312 36322	paclitaxel
T887	indication 36785 36811	Non-Small Cell Lung Cancer
T889	tradename 36851 36860	ABRAXANE/
T891	activeingredient 36897 36907	paclitaxel
T893	indication 37040 37074	non-small cell lung cancer (NSCLC)
T895	tradename 37125 37133	ABRAXANE
T897	routeofadministration 37157 37168	intravenous
T899	dose 37207 37216	100 mg/m2
T901	tradename 37262 37262	
T903	activeingredient 37262 37272	Paclitaxel
T905	routeofadministration 37306 37317	intravenous
T907	dose 37353 37362	200 mg/m2
T909	routeofadministration 37481 37494	intravenously
T911	tradename 37545 37554	ABRAXANE/
T913	activeingredient 37554 37564	paclitaxel
T915	activeingredient 37595 37605	paclitaxel
T917	tradename 38092 38100	ABRAXANE
T919	activeingredient 38112 38122	paclitaxel
T921	tradename 38346 38354	ABRAXANE
T923	tradename 38588 38596	ABRAXANE
T925	activeingredient 38634 38644	paclitaxel
T927	tradename 38869 38877	ABRAXANE
T929	dose 38879 38888	100 mg/m2
T931	frequency 38889 38896	weekly)
T933	tradename 38915 38915	
T935	activeingredient 38915 38925	Paclitaxel
T937	dose 38937 38946	200 mg/m2
T939	frequency 38947 38961	every 3 weeks)
T941	tradename 39149 39158	ABRAXANE/
T943	activeingredient 39212 39222	paclitaxel
T945	activeingredient 39288 39298	paclitaxel
T947	tradename 39544 39552	ABRAXANE
T949	activeingredient 39631 39641	paclitaxel
T951	tradename 39876 39884	ABRAXANE
T953	dose 39886 39895	100 mg/m2
T955	frequency 39896 39903	weekly)
T957	activeingredient 39926 39936	Paclitaxel
T959	dose 39948 39957	200 mg/m2
T961	frequency 39958 39972	every 3 weeks)
T963	tradename 40501 40509	ABRAXANE
T965	tradename 40782 40794	ABRAXANE.  
T967	indication 40828 40858	Adenocarcinoma of the Pancreas
T969	tradename 40921 40929	ABRAXANE
T971	indication 41030 41071	metastatic adenocarcinoma of the pancreas
T973	tradename 41216 41225	ABRAXANE/
T975	tradename 41380 41389	ABRAXANE/
T977	tradename 41481 41489	ABRAXANE
T979	tradename 41691 41699	ABRAXANE
T981	tradename 41898 41907	ABRAXANE/
T983	tradename 41924 41933	ABRAXANE(
T985	dose 41933 41943	125 mg/m2)
T987	tradename 42121 42130	ABRAXANE/
T989	tradename 42238 42247	ABRAXANE/
T991	tradename 42346 42355	ABRAXANE/
T993	tradename 42548 42556	ABRAXANE
T995	tradename 42774 42783	ABRAXANE/
T997	tradename 42838 42846	ABRAXANE
T999	dose 42848 42858	125 mg/m2)
T1001	tradename 44432 44441	ABRAXANE/
T1003	tradename 44507 44515	ABRAXANE
T1005	dose 44517 44527	125 mg/m2)
T1007	indication 45096 45126	adenocarcinoma of the pancreas
T1009	tradename 45140 45149	ABRAXANE/
T1011	tradename 45460 45469	ABRAXANE/
T1013	tradename 45670 45678	ABRAXANE
T1015	tradename 45717 45725	ABRAXANE
T1017	tradename 45836 45852	ABRAXANE-treated
T1019	tradename 45910 45918	ABRAXANE
T1021	tradename 45995 46004	ABRAXANE/
T1023	tradename 46288 46297	ABRAXANE/
T1025	tradename 46394 46402	ABRAXANE
T1027	tradename 46468 46476	ABRAXANE
T1029	activeingredient 46487 46497	Paclitaxel
T1031	tradename 46646 46657	ABRAXANE. 
T1033	activeingredient 46908 46918	paclitaxel
T1035	tradename 46959 46970	ABRAXANE. 
T1037	tradename 47075 47087	ABRAXANE. 
T1039	tradename 47098 47106	ABRAXANE
T1041	activeingredient 47161 47171	paclitaxel
T1043	corecomposition 47191 47198	albumin
T1045	tradename 47352 47364	ABRAXANE. 
T1047	tradename 47614 47622	ABRAXANE
T1049	activeingredient 47795 47805	paclitaxel
T1051	tradename 47853 47865	ABRAXANE.  
T1053	activeingredient 48112 48122	paclitaxel
T1055	tradename 48204 48215	ABRAXANE. 
T1057	tradename 48312 48320	ABRAXANE
T1059	activeingredient 48581 48591	paclitaxel
T1061	tradename 48633 48641	ABRAXANE
T1063	tradename 48798 48806	ABRAXANE
T1065	activeingredient 48958 48968	paclitaxel
T1067	tradename 49111 49123	ABRAXANE. 
T1069	tradename 49202 49210	ABRAXANE
T1071	activeingredient 49421 49431	paclitaxel
T1073	activeingredient 49510 49520	paclitaxel
T1075	activeingredient 49717 49727	paclitaxel
T1077	tradename 49944 49956	ABRAXANE. 
T1079	activeingredient 50313 50323	paclitaxel
T1081	tradename 50399 50407	ABRAXANE
T1083	activeingredient 50458 50468	paclitaxel
T1085	activeingredient 50673 50683	paclitaxel
T1087	tradename 50767 50775	ABRAXANE
T1089	tradename 51265 51277	ABRAXANE. 
T1091	tradename 51335 51343	ABRAXANE
T1093	tradename 51669 51680	ABRAXANE. 
T1095	activeingredient 51698 51708	paclitaxel
T1097	corecomposition 51723 51736	albumin-bound
T1099	dose 51811 51818	6 mg/m2
T1101	dose 52353 52360	3 mg/m2
T1103	activeingredient 52487 52497	paclitaxel
T1105	activeingredient 52525 52535	Paclitaxel
T1107	tradename 52924 52932	ABRAXANE
T1109	tradename 53058 53066	ABRAXANE
T1111	indication 53088 53112	metastatic breast cancer
T1113	tradename 53261 53272	ABRAXANE. 
T1115	tradename 53329 53337	ABRAXANE
T1117	indication 53386 53412	non-small cell lung cancer
T1119	tradename 53856 53864	ABRAXANE
T1121	tradename 54304 54312	ABRAXANE
T1123	activeingredient 54533 54543	paclitaxel
T1125	tradename 54650 54658	ABRAXANE
T1127	tradename 54748 54756	ABRAXANE
T1129	indication 54964 55005	metastatic adenocarcinoma of the pancreas
T1131	tradename 55156 55164	ABRAXANE
T1133	tradename 55562 55570	ABRAXANE
T1135	tradename 55734 55743	 ABRAXANE
T1137	nanoparticle 55771 55805	paclitaxel protein-bound particles
T1139	corecomposition 55834 55847	albumin-bound
T1141	nanoparticle 55852 55904	paclitaxel formulated as albumin-bound nanoparticles
T1143	particlediameter 55948 55963	130 nanometers.
T1145	tradename 55965 55965	
T1147	activeingredient 55965 55975	Paclitaxel
T1149	tradename 56039 56047	ABRAXANE
T1151	inactiveingredient 56148 56163	Sodium Chloride
T1153	routeofadministration 56188 56199	intravenous
T1155	activeingredient 56251 56261	paclitaxel
T1157	corecomposition 56278 56286	albumin)
T1159	corecomposition 56321 56328	albumin
T1161	inactiveingredient 56341 56357	sodium caprylate
T1163	inactiveingredient 56362 56389	sodium acetyltryptophanate)
T1165	nanoparticle 56455 56504	paclitaxel formulated as albumin-bound particles.
T1167	tradename 56505 56513	ABRAXANE
T1169	tradename 56556 56564	ABRAXANE
T1171	activeingredient 56568 56578	paclitaxel
T1173	chemoclass 56582 56604	microtubule inhibitor.
T1175	activeingredient 56628 56638	paclitaxel
T1177	activeingredient 56642 56643	5
T1179	activeingredient 56646 56651	20- 1
T1181	activeingredient 56652 56653	2
T1183	activeingredient 56656 56657	4
T1185	activeingredient 56658 56659	7
T1187	activeingredient 56662 56664	10
T1189	activeingredient 56667 56700	13 -hexahydroxytax-11-en-9-one 4
T1191	activeingredient 56701 56742	10-diacetate 2-benzoate 13-ester with (2R
T1193	activeingredient 56743 56775	3S)-N-benzoyl-3-phenylisoserine.
T1195	tradename 56777 56777	
T1197	activeingredient 56777 56787	Paclitaxel
T1199	tradename 56827 56827	
T1201	activeingredient 56827 56837	Paclitaxel
T1203	activeingredient 56908 56918	C47H51NO14
T1205	molecularweight 56945 56952	853.91.
T1207	tradename 57097 57105	ABRAXANE
T1209	chemoclass 57111 57132	microtubule inhibitor
T1211	tradename 57435 57435	
T1213	activeingredient 57435 57445	Paclitaxel
T1215	activeingredient 57643 57653	paclitaxel
T1217	tradename 57695 57703	ABRAXANE
T1219	dose 57722 57737	80 to 375 mg/m2
T1221	activeingredient 57813 57823	paclitaxel
T1223	tradename 57827 57838	ABRAXANE. 
T1225	routeofadministration 57848 57859	intravenous
T1227	tradename 57878 57886	ABRAXANE
T1229	activeingredient 57888 57898	paclitaxel
T1231	dose 58146 58161	80 to 300 mg/m2
T1233	activeingredient 58190 58200	paclitaxel
T1235	tradename 58205 58213	ABRAXANE
T1237	routeofadministration 58250 58261	intravenous
T1239	dose 58307 58316	260 mg/m2
T1241	tradename 58317 58325	ABRAXANE
T1243	dose 58405 58414	175 mg/m2
T1245	activeingredient 58415 58425	paclitaxel
T1247	tradename 58540 58548	ABRAXANE
T1249	activeingredient 58558 58568	paclitaxel
T1251	tradename 58657 58665	ABRAXANE
T1253	activeingredient 58712 58722	paclitaxel
T1255	activeingredient 58882 58892	paclitaxel
T1257	tradename 58933 58941	ABRAXANE
T1259	activeingredient 58973 58983	paclitaxel
T1261	activeingredient 59054 59064	paclitaxel
T1263	tradename 59070 59078	ABRAXANE
T1265	activeingredient 59107 59117	paclitaxel
T1267	activeingredient 59218 59228	paclitaxel
T1269	activeingredient 59396 59407	paclitaxel.
T1271	volumeofdistribution 59459 59465	1741 L
T1273	activeingredient 59572 59583	paclitaxel.
T1275	activeingredient 59673 59683	paclitaxel
T1277	activeingredient 59860 59870	paclitaxel
T1279	activeingredient 60345 60355	paclitaxel
T1281	dose 60570 60585	80 to 300 mg/m2
T1283	activeingredient 60615 60625	paclitaxel
T1285	clearance 60638 60653	13 to 30 L/h/m2
T1287	plasmahalflife 60699 60714	13 to 27 hours.
T1289	dose 60746 60755	260 mg/m2
T1291	tradename 60765 60773	ABRAXANE
T1293	activeingredient 61224 61234	paclitaxel
T1295	tradename 61245 61253	ABRAXANE
T1297	activeingredient 61500 61511	paclitaxel.
T1299	activeingredient 61748 61758	paclitaxel
T1301	activeingredient 61798 61808	paclitaxel
T1303	activeingredient 62013 62023	paclitaxel
T1305	tradename 62327 62335	ABRAXANE
T1307	indication 62453 62494	metastatic adenocarcinoma of the pancreas
T1309	activeingredient 62814 62824	paclitaxel
T1311	tradename 62835 62843	ABRAXANE
T1313	activeingredient 63053 63063	paclitaxel
T1315	tradename 63172 63180	ABRAXANE
T1317	activeingredient 63446 63457	paclitaxel.
T1319	tradename 63499 63507	ABRAXANE
T1321	tradename 63594 63602	ABRAXANE
T1323	indication 63629 63634	NSCLC
T1325	activeingredient 63682 63692	paclitaxel
T1327	activeingredient 63909 63920	paclitaxel.
T1329	tradename 63961 63969	ABRAXANE
T1331	tradename 64023 64031	ABRAXANE
T1333	tradename 64200 64208	ABRAXANE
T1335	tradename 64232 64232	
T1337	activeingredient 64232 64242	Paclitaxel
T1339	tradename 64356 64364	ABRAXANE
T1341	activeingredient 64457 64467	paclitaxel
T1343	corecomposition 64482 64495	albumin-bound
T1345	dose 64926 64940	3 and 12 mg/m2
T1347	frequency 64940 64945	/week
T1349	activeingredient 65154 65164	paclitaxel
T1351	corecomposition 65179 65192	albumin-bound
T1353	dose 65262 65270	54 mg/m2
T1355	dose 65286 65295	175 mg/m2
T1357	indication 65334 65358	Metastatic Breast Cancer
T1359	tradename 65530 65538	ABRAXANE
T1361	indication 65542 65567	metastatic breast cancer.
T1363	tradename 65615 65623	ABRAXANE
T1365	dose 65678 65687	175 mg/m2
T1367	indication 65708 65733	metastatic breast cancer.
T1369	dose 65771 65780	300 mg/m2
T1371	indication 65825 65850	metastatic breast cancer.
T1373	indication 66042 66067	metastatic breast cancer.
T1375	tradename 66106 66114	ABRAXANE
T1377	dose 66128 66137	260 mg/m2
T1379	activeingredient 66172 66182	paclitaxel
T1381	dose 66196 66205	175 mg/m2
T1383	tradename 66811 66819	ABRAXANE
T1385	activeingredient 67040 67050	paclitaxel
T1387	indication 67233 67257	Metastatic Breast Cancer
T1389	tradename 67265 67273	ABRAXANE
T1391	dose 67274 67283	260 mg/m2
T1393	tradename 67285 67285	
T1395	activeingredient 67285 67295	Paclitaxel
T1397	dose 67306 67315	175 mg/m2
T1399	indication 68282 68308	Non-Small Cell Lung Cancer
T1401	indication 68415 68441	non-small cell lung cancer
T1403	tradename 68453 68461	ABRAXANE
T1405	activeingredient 68497 68507	paclitaxel
T1407	indication 68600 68627	non-small cell lung cancer.
T1409	tradename 68629 68637	ABRAXANE
T1411	routeofadministration 68661 68672	intravenous
T1413	dose 68711 68720	100 mg/m2
T1415	tradename 68766 68766	
T1417	activeingredient 68766 68776	Paclitaxel
T1419	routeofadministration 68810 68821	intravenous
T1421	dose 68857 68866	200 mg/m2
T1423	routeofadministration 68985 68998	intravenously
T1425	tradename 69049 69058	ABRAXANE/
T1427	activeingredient 69058 69068	paclitaxel
T1429	tradename 69659 69668	ABRAXANE/
T1431	activeingredient 69775 69785	paclitaxel
T1433	indication 69990 70016	Non-Small Cell Lung Cancer
T1435	tradename 70053 70061	ABRAXANE
T1437	dose 70063 70072	100 mg/m2
T1439	frequency 70073 70080	weekly)
T1441	tradename 70105 70105	
T1443	activeingredient 70105 70115	Paclitaxel
T1445	dose 70127 70136	200 mg/m2
T1447	frequency 70137 70151	every 3 weeks)
T1449	indication 70669 70699	Adenocarcinoma of the Pancreas
T1451	tradename 70800 70808	ABRAXANE
T1453	indication 70884 70926	metastatic adenocarcinoma of the pancreas.
T1455	tradename 71564 71573	ABRAXANE/
T1457	tradename 71854 71863	ABRAXANE/
T1459	tradename 71884 71892	ABRAXANE
T1461	dose 71893 71902	125 mg/m2
T1463	routeofadministration 71909 71920	intravenous
T1465	dose 71973 71983	1000 mg/m2
T1467	routeofadministration 71990 72001	intravenous
T1469	dose 72119 72129	1000 mg/m2
T1471	routeofadministration 72136 72147	intravenous
T1473	dose 72247 72257	1000 mg/m2
T1475	indication 73269 73299	Adenocarcinoma of the Pancreas
T1477	tradename 73318 73327	ABRAXANE(
T1479	dose 73327 73337	125 mg/m2)
T1481	tradename 73958 73966	ABRAXANE
T1483	activeingredient 75639 75649	paclitaxel
T1485	tradename 76240 76248	ABRAXANE
T1487	tradename 76439 76447	ABRAXANE
T1489	tradename 76574 76582	ABRAXANE
T1491	tradename 77054 77062	ABRAXANE
T1493	tradename 77310 77318	ABRAXANE
T1495	company 77672 77691	Celgene Corporation
T1497	tradename 77711 77719	ABRAXANE
T1499	company 77750 77768	Abraxis BioScience
T1501	company 77770 77774	LLC.
T1503	company 77787 77805	Abraxis BioScience
T1505	company 77807 77811	LLC.
T1507	tradename 77835 77835	
T1509	company 77835 77853	Abraxis BioScience
T1511	company 77855 77858	LLC
T1513	company 77891 77911	Celgene Corporation.
T1515	tradename 78003 78013	 ABRAXANE
T1517	activeingredient 78031 78041	paclitaxel
T1519	corecomposition 78094 78107	albumin-bound
T1521	tradename 78167 78175	ABRAXANE
T1523	tradename 78328 78347	ABRAXANE? ABRAXANE
T1525	indication 78502 78528	non-small cell lung cancer
T1527	tradename 78771 78779	ABRAXANE
T1529	tradename 78839 78850	ABRAXANE? 
T1531	tradename 78865 78873	ABRAXANE
T1533	tradename 78979 78991	ABRAXANE.  
T1535	tradename 79037 79046	ABRAXANE?
T1537	tradename 79066 79074	ABRAXANE
T1539	tradename 79264 79284	ABRAXANE.  ABRAXANE
T1541	tradename 79420 79428	ABRAXANE
T1543	tradename 79503 79512	ABRAXANE.
T1545	tradename 79672 79683	ABRAXANE. 
T1547	tradename 79743 79751	ABRAXANE
T1549	tradename 79836 79844	ABRAXANE
T1551	tradename 80129 80140	ABRAXANE? 
T1553	tradename 80171 80179	ABRAXANE
T1555	tradename 80309 80320	ABRAXANE. 
T1557	tradename 80388 80399	ABRAXANE. 
T1559	tradename 80436 80444	ABRAXANE
T1561	tradename 80472 80480	ABRAXANE
T1563	routeofadministration 80505 80516	intravenous
T1565	tradename 80603 80615	ABRAXANE.  
T1567	tradename 80653 80673	ABRAXANE? ABRAXANE
T1569	tradename 80755 80763	ABRAXANE
T1571	tradename 81026 81034	ABRAXANE
T1573	tradename 81209 81217	ABRAXANE
T1575	tradename 81458 81466	ABRAXANE
T1577	tradename 81711 81719	ABRAXANE
T1579	tradename 81790 81798	ABRAXANE
T1581	tradename 82460 82471	ABRAXANE. 
T1583	tradename 82692 82703	ABRAXANE. 
T1585	tradename 82886 82897	ABRAXANE. 
T1587	tradename 83014 83022	ABRAXANE
T1589	tradename 83139 83150	ABRAXANE? 
T1591	activeingredient 83169 83179	paclitaxel
T1593	corecomposition 83196 83204	albumin)
T1595	corecomposition 83232 83239	albumin
T1597	inactiveingredient 83252 83268	sodium caprylate
T1599	inactiveingredient 83273 83300	sodium acetyltryptophanate)
T1601	company 83436 83455	Celgene Corporation
T1603	tradename 83474 83482	ABRAXANE
T1605	company 83513 83531	Abraxis BioScience
T1607	company 83533 83537	LLC.
T1609	company 83550 83568	Abraxis BioScience
T1611	company 83570 83574	LLC.
T1613	tradename 83598 83598	
T1615	company 83598 83616	Abraxis BioScience
T1617	company 83618 83621	LLC
T1619	company 83654 83674	Celgene Corporation.
